A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)

被引：1
|
作者：
Cheng, Y. [1 ]
Qin, Z. [2 ]
Meng, X. [3 ]
Xu, F. [4 ]
Wang, Y. [5 ]
Yao, Y. [6 ]
Fang, J. [7 ]
Zhao, Y. [8 ]
机构：
[1] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Med Oncol, Hangzhou, Peoples R China
[3] Shandong Canc Hosp, Radiat Oncol, Jinan, Peoples R China
[4] Nanchang Univ, Resp Med, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[5] Harbin Med Univ, Resp Med, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[6] Xi An Jiao Tong Univ, Med Oncol, Affiliated Hosp 1, Xian, Peoples R China
[7] Peking Univ, Thorac Med Oncol, Canc Hosp, Beijing, Peoples R China
[8] Henan Canc Hosp, Resp Med, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1992P
引用
收藏
页码：S1062 / S1062
页数：1
相关论文
共 50 条
  • [1] Updated phase II efficacy and safety results of BNT327/ PM8002 combined with paclitaxel as second-line (2L) therapy in small cell lung cancer (SCLC)
    Cheng, Y.
    Luo, Y.
    Meng, X.
    Sun, L.
    Yao, Y.
    Fang, J.
    Zhang, P.
    Qin, Z.
    Wang, Y.
    Hu, H. H.
    Zhao, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03)
  • [2] A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Wu, Jiong
    Zhang, Jian
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Yong-Sheng
    Cheng, Qiao
    Chen, Xin
    Li, Zhihua
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [3] PHASE I SAFETY AND PRELIMINARY EFFICACY OF PM8002 IN SUBJECTS WITH ADVANCED SOLID TUMORS, A BISPECIFIC ANTIBODY TARGETING PD-L1 AND VEGF-A
    Guo, Ye
    Luo, Suxia
    Qin, Yanru
    Yin, Yongmei
    Li, Guiling
    Wang, Jingfen
    Li, Yongsheng
    Guo, Jun
    Zhang, Feng
    Huang, Yi
    Luo, Hong
    Lv, Dongqing
    Ying, Cheng
    Wang, Chunyan
    Chou, Chuan-Chu
    Gong, Chundan
    Chang, Ruixia
    Liu, Jing
    Hu, Guoqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A758 - A758
  • [4] Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors
    Guo, Ye
    Guo, Jun
    Cheng, Ying
    Wang, Zhen
    Li, Yongsheng
    Lv, Dongqing
    Yin, Yongmei
    Li, Guiling
    Wu, Lingying
    Huang, Yi
    Wei, Shuqing
    Shen, Lin
    Duan, Huaxin
    Cui, Jiuwei
    Luo, Hong
    Li, Xiumin
    Nan, Kejun
    Wang, Chunyan
    Luo, Su-Xia
    Liu, Ruonan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC
    Wu, Chunjiao
    Lv, Dongqing
    Cui, Jiuwei
    Wang, Zhen
    Zhao, Hui
    Duan, Huaxin
    Duan, Ping
    Yin, Yongmei
    Pan, Yueyin
    Liu, Fu-Nan
    Kong, Chuize
    Zhang, Jian
    Li, Yongsheng
    Han, Xinpeng
    Liu, Baogang
    He, Lijie
    Qin, Zhiquan
    Wu, Tao
    Ji, Mei
    Cheng, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
    Sheng, X.
    Luo, H.
    Kong, C.
    Liu, F.
    Wei, S.
    Wang, Z.
    Guo, Y.
    Yin, Y.
    Zhao, H.
    Li, G.
    Wu, B.
    Li, Y.
    Nan, K.
    Ke, M.
    Wu, T.
    Zhang, J.
    Wang, Z.
    Li, X.
    Lei, K.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1014 - S1014
  • [7] A PHASE II STUDY OF WEEKLY PACLITAXEL PLUS GEMCITABINE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SMALL CELL LUNG CANCER (SCLC)
    Kim, H. T.
    Yun, T.
    Han, J.
    Choi, H. L.
    Kim, H. Y.
    Lee, J. S.
    LUNG CANCER, 2009, 64 : S62 - S62
  • [8] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer
    Yu, Lian
    Xu, Jianlin
    Qiao, Rong
    Han, Baohui
    Zhong, Hua
    Zhong, Runbo
    CANCER MEDICINE, 2023, 12 (05): : 5372 - 5383
12345